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Background. Although diabetic kidney disease (DKD) could affect up to one-third of patients with diabetes mellitus (DM), these
patients can develop kidney diseases different from DKD, or these conditions can superimpose on DKD. Several potential
predictors of nondiabetic kidney disease (NDKD) have been proposed, but there are no definitive indications available for kidney
biopsy in diabetic patients. Methods. We designed a single-center, cross-sectional, and retrospective cohort study to identify
clinical and laboratory factors associated with a diagnosis of NDKD after native kidney biopsy in diabetic patients and to
investigate differences in time to end-stage kidney disease (ESKD) in patients with a diagnosis of DKD and NDKD. Results. Of 142
patients included in our analysis, 89 (62.68%) had a histopathological diagnosis of NDKD ormixed NDKD+DKD. Patients in the
NDKD group had significantly lower HbA1C, lower prevalence of diabetic retinopathy (DR), and less severe proteinuria, and
there was a lower proportion of patients with nephrotic syndrome; the DKD group had significantly lower proportion of patients
with hematological conditions. In the multivariate binary logistic regression, only absence of DR and presence of a hematological
condition significantly predicted NDKD after adjustment for age and sex. Time to ESKD was significantly higher in patients with
NDKD or mixed forms than in those with DKD. Conclusions. After a careful selection, more than half of kidney biopsies
performed in diabetic patients can identify NDKD (alone or with concomitant DKD). Absence of DR and coexistence of a
hematological condition (especially MGUS) were strong predictors of NDKD in our cohort.
1. Introduction
(e global burden of diabetes mellitus (DM) has substan-
tially increased in the last decades, mostly due to a rise in the
prevalence of type 2 DM secondary to obesity and the
metabolic syndrome [1]. Approximately 25 to 30 percent of
diabetic patients will develop diabetic kidney disease (DKD),
and DM currently represents the leading cause of chronic
kidney disease (CKD) and end-stage kidney disease (ESKD)
worldwide [1, 2], with expected consequences in patients’
morbidity and mortality. Hyperglycemia-induced micro-
vascular changes in the kidney are responsible for the de-
velopment of diabetic nephropathy, or diabetic
kidney disease (DKD), a condition with distinctive
histopathological features (i.e., glomerular and tubular
basement membrane thickening, mesangial matrix expan-
sion with nodule formation, hyaline material accumulation
in the glomerular capillary loops, and arteriolar hyalinosis)
[1, 3]. Although novel therapeutic approaches are emerging
or under study [4], treatment of diabetic nephropathy
presently largely relies on nonspecific interventions, with
therapeutic goals consisting in maintaining a tight glycemic
control, using renin-angiotensin-aldosterone inhibitors to
reduce glomerular hyperfiltration and proteinuria, and
ensuring adequate control of blood pressure and other
cardiovascular risk factors. Despite being defined as a his-
topathological entity, the diagnosis of DKD is most often
based only on clinical and laboratory parameters, and a
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kidney biopsy is generally not required for confirmation,
even if this would be the only way to determine if kidney
dysfunction is a direct consequence of the diabetic envi-
ronment [1]. (e cardinal factors considered as associated
with DKD in diabetic patients are the progression from
microalbuminuria to overt proteinuria over time and a
(relatively slow) decrease in glomerular filtration rate (GFR),
after a phase of hyperfiltration, generally with an enlarged
normal-sized kidney on ultrasound [3].
Diabetic patients can develop kidney diseases different
from DKD, or these conditions can superimpose on DKD;
since clinical presentation is generally nonspecific (kidney
dysfunction and proteinuria), clinicians are less prone to
perform diagnostic kidney biopsy in these patients and
could erroneously provide a presumptive diagnosis of
DKD, limiting the access to specific treatments. (e in-
dication to kidney biopsy in a patient with DM and kidney
dysfunction and/or proteinuria represents a clinical co-
nundrum, and several studies have attempted to identify
clinical and laboratory factors associated with a histo-
pathological diagnosis of nondiabetic kidney disease
(NDKD) in order to restrict biopsy to patients with a high
probability of being candidates to different therapeutic
interventions. Clinically accepted predictors of NDKD in
diabetic patients are the absence of DR, sudden onset of
nephrotic syndrome or nephrotic-range proteinuria, short
duration of diabetes, microscopic hematuria (especially
with dysmorphic erythrocytes), and low glycated hemo-
globin levels [5]. However, the generalizability of the
aforementioned findings might be low in selected pop-
ulations (for instance, in a recent meta-analysis of 48
studies, more than a half reported data on patients of Asian
descent [6]), and there are no definitive indications
available for kidney biopsy, often leaving the decision to
single-center policies.
(e performance of kidney biopsy in diabetic patients
has also been proved to provide prognostic information;
indeed, patients with DKD have been reported to have
shorter renal survival compared to patients with NDKD
[7–9]. Although data on patient survival are less uniformly
reported, a recent study identified a diagnosis of DKD as a
risk factor for mortality [7].
(e aim of our study was to investigate the clinical and
laboratory factors associated with a diagnosis of NDKD in a
cohort of patients with DM who underwent kidney biopsy
on clinical indication. We also investigated differences in
renal and patient survival among patients with DKD or
NDND.
2. Materials and Methods
We designed a single-center, retrospective, cross-sectional,
and cohort study to identify clinical and laboratory factors
associated with a histopathological diagnosis of NDKD after
native kidney biopsy in diabetic patients (including under
the term NDKD also patients with mixed forms,
NDKD+DKD) and to investigate differences in time to
ESKD in patients with a diagnosis of DKD and NDKD after
kidney biopsy. We enrolled all adult patients with a
diagnosis of type I or type II DM who underwent diagnostic
native kidney biopsy on clinical indication at the Ne-
phrology and Dialysis Unit, University Hospital of Modena,
Modena, Italy, from January 1, 2010, to April 30, 2020. (e
study was approved by the local ethical committee
(“Comitato Etico dell’Area Vasta Emilia Nord” (protocol no.
252/2020)).
Data were collected from clinical charts and histo-
pathological reports; patients with incomplete clinical or
laboratory data or with inadequate samples in kidney biopsy
were excluded from the analysis. (e following clinical
variables at kidney biopsy were considered: age, sex, body
mass index (BMI), blood pressure, presence of nephrotic
syndrome, acute kidney injury, need for dialysis, type of
diabetes, presence of DR, diabetes duration, presence of
hematological conditions, and history of cardiovascular
diseases (previous myocardial infarction or stroke). Labo-
ratory data at biopsy included the following: serum creati-
nine and estimated GFR (eGFR) according to the CKD-EPI
equation, 24 h proteinuria or proteinuria/creatininuria on a
single-void urine sample, serum albumin, presence of
microhematuria, serum cholesterol levels, serum comple-
ment levels (C3/C4), antinuclear antibody (ANA) and
antineutrophil cytoplasm antibody (ANCA) positivity,
antiphospholipase A2 receptor (PLA2R) positivity, viral
serologies for hepatitis B virus (HBV), hepatitis C virus
(HCV), and human immunodeficiency virus (HIV), and
glycated hemoglobin (HbA1C). Nephrotic syndrome was
defined as the combination of proteinuria of more than 3.5 g
per day, hypoalbuminemia (less than 3.5 g/dl), and edema.
Acute kidney injury was defined according to the KDIGO
criteria [10]. We defined “hematological condition” as the
presence of monoclonal gammopathy of undetermined
significance (MGUS), monoclonal B-cell lymphocytosis
(MBL), or multiple myeloma (MM).
Renal biopsy was performed on clinician discretion, and
indications included the following (alone or in combination):
nephrotic syndrome (especially if of sudden onset and in
patients without DR), subnephrotic proteinuria in patients
with a DM duration of less than 5 years, rapidly progressive
kidney dysfunction with or without urinary abnormalities, and
acute kidney injury without convincing clinical explanation.
Histological examination, performed by one of two expert
nephropathologists, was conducted on light microscopy for
Bouin medium-fixed paraffin-embedded tissue with standard
staining and immunofluorescence analysis for fresh frozen
tissue with standard antisera; electronmicroscopy analysis was
performed in a minority of cases on clinician indication and if
dedicated material was available. Histological features of DKD
were diffuse mesangial sclerosis with or without nodule for-
mation and glomerular basement membrane thickening;
supportive features were tubular basement membrane thick-
ening (in nonatrophic tubules), presence of glomeruli (fibrin
caps and capsular drop), and arteriolar hyalinosis.
Statistical analysis was performed using GraphPad Prism
(version 6.01) and SPSS (version 23) software. Continuous
data were reported as median and interquartile range or
mean and standard deviation as appropriate and discrete
data as absolute number and relative percentage; data were
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compared with Student’s t-test, Kruskal–Wallis test, and chi-
square test as appropriate. Univariate binary logistic re-
gression was used to identify independent factors predictive
of NDKD; a multivariate logistic regression model adjusting
for age and sex was then developed including all variables
with p< 0.1. Differences in time to ESKD (defined as the
need of renal replacement treatment, RRT) and death among
the DKD group and the NDKD and mixed DKD+NDKD
group were estimated with the Kaplan–Meier method with
log-rank test.
3. Results
We screened 203 diabetic patients who underwent diag-
nostic kidney biopsy at our center; after exclusion of biopsies
performed in kidney-transplanted patients and of cases with
insufficient material for a diagnosis, 142 patients were in-
cluded in our analysis. Of them, 53 patients (37.32%) had a
diagnosis of DKD in kidney biopsy, 28 (19.72%) of NDKD
with mixed DKD, and 61 (42.96%) of isolated NDKD (see
Figure 1). Clinical and laboratory data at the time of kidney
biopsy are summarized in Table 1. (e average age of pa-
tients was 62.65± 12.35 years, and most were males (72.5%)
and of Caucasian descent (88.03%); average duration of DM
was 11.9± 9.7 years. Diabetic patients who received kidney
biopsy presented with significant kidney dysfunction, with
an average eGFR of 36.2± 27.02ml/min, and urinary ab-
normalities (median proteinuria/creatininuria: 3.895 g/g,
IQR: 1.195–6.925, and microhematuria in 62.68% of pa-
tients). In the DKD group, there was a lower proportion of
Caucasian patients (79.2%), while patients in the NDKD
group had significantly lower systolic blood pressure, shorter
duration of diabetes (median: 6 years; IQR: 3–11), lower
HbA1C levels (43.5mmol/mol; IQR: 38.2–53.7), and lower
prevalence of DR (13.1%). (e NDKD group showed less
severe proteinuria, with lower proteinuria/creatininuria
(median: 2 g/g; IQR: 0.6–4.3), higher serum albumin levels
(3.5 g/dl, IQR: 3.0–4.0), and lower proportion of patients
with nephrotic syndrome (27.9%). Of note, there were no
differences between the groups in the proportion of patients
presenting with microhematuria. Interestingly, a signifi-
cantly lower proportion of patients with DKD compared
with other groups carried a diagnosis of a hematological
condition. Conversely, we encountered no differences
among the groups in the proportion of patients who had a
positive serology for chronic viral infections or autoimmune
diseases nor in the levels of serum complement fractions C3
and C4.
Eighty-nine diabetic patients received a main histo-
logical diagnosis different from DKD (in 28 of them, there
was coexistence of NDKD and DKD). (e most frequent
diagnosis in the NDKD and NDKD+DKD groups was
membranous nephropathy (19.1%), hypertensive reno-
vascular disease (8.99%), chronic nephropathy—not
otherwise specified (7.87%), membranoproliferative glo-
merulonephritis (not further specified) (6.74%), and IgA
nephropathy (6.74%). (e complete list of diagnosis in the
NDKD and NDKD+DKD groups is depicted in Figure 2.
Of the 89 patients who received a main diagnosis of
NDKD, 46 revealed histological lesions that altered
treatment decision, prompting specific (immunosup-
pressive) treatment.
Twenty patients had a hematological condition, mostly
benign; the majority of them (85%) had a diagnosis of
MGUS, 2 had MM, and 1 had MBL; 2 patients with MGUS
also had cryoglobulinemia (of unspecified type). Histological
diagnosis obtained from kidney biopsy of the 20 patients
with hematological conditions and NDKD is reported in
Table 2.
To identify independent predictors of NDKD in kidney
biopsy, we tested several factors in a preliminary univariate
analysis. (e following variables were included in the final
multivariate model: diabetes duration, nephrotic syndrome,
DR, hematological condition, and HbA1C. After adjustment
for age and sex, only the absence of DR and the presence of a
hematological condition maintained significance in pre-
dicting the specified outcome (see Table 3).
With respect to long-term kidney outcome of our cohort,
roughly one-third of patients (n� 45) developed ESKD
during follow-up. We encountered a higher proportion of
patients needing RRT in the DKD group (n� 26, 49%) with
respect to the NDKD (n� 10, 16%) and the mixed groups
(n� 9, 32%); four patients (1 in the DKD, 1 in the mixed, and
2 in the DKD groups) were on dialysis at the time of kidney
biopsy. Time to ESKD was significantly shorter in the DKD
group, as shown by the Kaplan–Meier curves in Figure 3(a)
(log-rank test, p � 0.0008). We did not identify difference in
patient survival comparing the two groups (see Figure 3(b)).
4. Discussion
In our cohort of 142 diabetic patients who required kidney
biopsy, NDKD was identified in 62.68% of patients (with 61
patients having isolated NDKD and 28 NDKD and coex-








Mixed NDKD + DKD
(n = 28)
Included in the analysis (n = 142)
Excluded (n = 61):
- Kidney transplant biopsy
(n = 57)
- Insufficient material in
kidney biopsy (n = 4)
Figure 1: Study design and patients’ selection.
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presence of a hematological condition were the strongest
predictors of NDKD as a main histopathological diagnosis.
Nephropathy represents a frequent microvascular
complication of DM, with up to one-third of patients being
reported to develop DKD in the course of their life. Nev-
ertheless, these patients can develop other types of kidney
disease, which require a different diagnostic and therapeutic
approach, and the frequency of these conditions in diabetic
patients is reasonably expected to grow with the steady
increase in the prevalence of DM worldwide.
With the present study, we showed that, in a carefully
selected population of diabetic patients, over a half received a
histological diagnosis of kidney pathology different from
DKD, allowing for a more precise diagnostic and prognostic
classification and, in a relevant proportion of cases, opening
the opportunity for specific treatments. Regarding this aspect,
our findings are in line with those from a recent study from
Spain including more than 800 diabetic patients (mostly
Caucasians), where NDKD and mixed NDKD+DKD were
diagnosed, respectively, in 49.6% and 10.8% [7]; similarly,
previous studies from the U.S. [11] and China [12] identified
alternative diagnosis to DKD in more than 50% of cases.
(ese data confirm that even if precise indications for kidney
biopsy in diabetic patients are lacking, clinical judgment based
on generally accepted parameters represents a fair discrimi-
nator; nevertheless, still a high proportion of biopsies yields a
diagnosis of DKD and potentially could have been avoided, at
least from the patients’ perspective.
Regarding the histopathological findings in the NDKD
and mixed NDKD+DKD groups, in our cohort, the most
frequent diagnosis was membranous nephropathy (almost
20% of cases in these groups). (is appears somewhat con-
flictive with the data from the aforementioned larger Spanish
court [7], where hypertensive nephrosclerosis was the
dominant finding alternative to DKD. A possible explanation
for this difference is that since most diabetic patients are also
hypertensive and considering that renal histological features
of the two conditions can easily overlap (for instance, arte-
riolosclerosis or arteriolar hyalinosis), we were very cautious
in proposing nephrosclerosis as a main diagnosis if DKD
features, even minimal, were present. Supporting our find-
ings, membranous nephropathy was also the most frequent
glomerular disease described in a previous Italian study [13].
Interestingly, many studies reported IgA nephropathy as the
main diagnosis alternative to superimposed DKD
[8, 9, 14, 15]. We consider that, among other factors, dif-
ferences in the ethnic background (i.e., proportion of patients
of Asian descent) could account for this lack of homogeneity.
Of note, compared with the data from Sharma et al. [11],
extrapolated from a large U.S. diabetic population, we had a
consistently lower number of diagnoses of acute tubular
injury, possibly reflecting also a substantial difference in
kidney biopsy indications among different countries.
Diabetes duration and levels of HbA1C have been
reported as important predictive factors for DKD in
previous studies [9]; nevertheless, we were not able to
Table 1: Clinical and laboratory characteristics of patients with DKD, NDKD, and mixed NDKD+DKD.
Variables All patients DKD MixedNDKD+DKD NDKD
p
value
No. of patients (%) 142 53 (37.32) 28 (19.72) 61 (42.96) –
Age (yr) 62.65± 12.35 59.9± 12.2 63.9± 12.6 64.5± 12.1 0.12
Males (%) 103 (72.5) 39 (73.6) 21 (75.0) 43 (70.5) 0.89
Race, Caucasians (%) 125 (88.03) 42 (79.2) 26 (92.8) 57 (93.4) 0.045
Type I DM (%) 5 (3.52) 3 (5.6) 1 (3.6) 1 (1.6) 0.5
BMI 28.7± 5.7 28.1± 5.1 30.0± 7.5 28.7± 5.4 0.36
Systolic blood pressure (mmHg) 138.7± 15.5 142.2± 16.2 138.5± 17.1 135.9± 13.7 0.09
Diastolic blood pressure (mmHg) 77.7± 9.6 77.8± 9.7 79.2± 8.5 76.9± 10.0 0.59
Diabetes duration (yr) 11.9± 9.7 14 (7–20) 12 (6.2–18.7) 6 (3–11) <0.001
Diabetic retinopathy (%) 49 (34.51) 32 (60.4) 9 (32.1) 8 (13.1) 0.001
Ischemic heart disease/stroke (%) 52 (36.62) 22 (41.5) 11 (39.3) 19 (31.1) 0.53
Smokers (%) 25 (17.73) 10 (18.9) 5 (17.9) 10 (16.4) 0.95
HbA1C (mmol/mol) 51.0± 14.55 49 (42–66) 50.5 (42.2–56.5) 43.5 (38.2–53.7) 0.04
Proteinuria/creatininuria 3.895 (1.195–6.925) 5 (3.6–8.5) 5.2 (0.9–9.6) 2 (0.6–4.3) <0.001
eGFR (ml/min) 36.2± 27.02 34.4± 33.2 31.9± 16.7 39.7± 33.2 0.37
Microhematuria (%) 89 (62.68) 34 (64.2) 21 (75.0) 34 (55.7) 0.21
s-albumin (g/dl) 3.329± 0.76 3.2 (2.8–3.7) 3.24 (2.7–3.8) 3.5 (3.0–4.0) 0.07
Hypercholesterolemia (%) 82 (57.75) 32 (60.4) 18 (64.3) 32 (52.5) 0.57
s-hemoglobin (g/dl) 11.09± 2.0 10.8± 1.6 11.0± 1.7 11.4± 2.4 0.36
Nephrotic syndrome (%) 59 (41.55) 28 (52.8) 14 (50.0) 17 (27.9) 0.02
Acute kidney injury (%) 49 (34.51) 16 (30.2) 9 (32.1) 24 (39.3) 0.6
s-C3 (mg/dl) 113.4± 17.1 114.6± 19.7 115.3± 33.3 111.5± 26.7 0.77
s-C4 (mg/dl) 26.78± 10.3 29.4± 10.2 25.3± 10.2 25.1± 10.2 0.06
ANA or ANCA or anti-PLA2R+ (%) 22 (15.49) 5 (9.4) 3 (10.7) 14 (23) 0.1
HBsAg or HCV or HIV+ (%) 19 (13.38) 4 (7.5) 4 (14.3) 11 (18) 0.26
Hematological conditions (MGUS, MM, and
MBL) (%) 21 (14.79) 2 (3.8) 6 (21.4) 13 (21.3) 0.02
4 International Journal of Nephrology
confirm this finding in our cohort. Indeed, while our
patients in the NDKD group showed a shorter duration of
diabetes and lower HbA1C levels, the significance of these
elements to predict the histological diagnosis was not
maintained in the logistic regression after adjustment for
other covariates. We hypothesize that the lack of signifi-
cance of these factors, which should be logically associated
with a higher “diabetes burden,” could be ascribed to the
relatively small size of our cohort. It must also be con-
sidered that self-reported duration of diabetes could be
imprecise and that patients could be diabetic for years
before being diagnosed as such. In sum, we presently tend
to consider these elements as of limited clinical utility, at
least in our diabetic population.
Similarly, the degree of proteinuria and the presence of
nephrotic syndrome, although significantly different among
the groups we examined (with patients with DKD presenting
with higher proteinuria and more frequent nephrotic syn-
drome), did not predict NDKD in the multivariate analysis.
Regarding this aspect, similar results were reported from
Sharma et al. [11]. (is finding underlines the absence of
specificity in the presentation of different kidney diseases, an
extremely common concept in clinical nephrology, and the
main reason justifying the use of kidney biopsy to obtain a
precise diagnosis. Certainly, these considerations strongly
apply to diabetic patients also with kidney dysfunction and
proteinuria. Due to the lack of specific data (before kidney
biopsy) in a considerable number of patients, we were not able
to assess the impact of the sudden onset of nephrotic syndrome
in the final histopathological diagnosis. Indeed, this factor
could have been of interest since it is commonly considered as
suggestive for NDKD, as opposed to the typical progression of
DKD from the stage of microalbuminuria through overt
proteinuria and eventually to nephrotic syndrome.
Diabetic patients withNDKDhave been reported to show a
slightly higher prevalence of microhematuria, especially with
dysmorphic erythrocytes, and this factor has been claimed as a
potential predictor of NDKD [16]. We did not identify dif-
ferences between our groups in the proportion of patients with
microhematuria, and we presently consider it as a rather
unspecific finding in patients with DM and kidney dysfunction
and/or proteinuria. Moreover, a recent study on 261 patients
with biopsy-proven DKD demonstrated the presence of he-
maturia in almost half of them [17]; interestingly, hematuria
was associated with more severe histological damage and
predicted a worse prognosis in this cohort.
Serological tests, such as markers of chronic viral infec-
tions, autoimmunity, and serum complement levels, are often
used in clinical practice to refine the indication to kidney
biopsy; this is considered especially useful in patients with
metabolic conditions such as diabetes and hypertension, which
Postinfectious GN (4)
Membranous nephropathy (17)
Hypertensive renovascular disease (9)
Chronic nephropathy- NOS (7)
Acute tubular necrosis (3)
ANCA-associated vasculitis (3)
Light-chain deposition disease (3)
Acute interstitial nephritis (4)









Light-chain cast nephropathy (1)
Mesangioproliferative GN (5)
Minimal change disease (1)
Focal segmental glomerulosclerosis (1)
Crescentic GN, NOS (1)
Normal (1)
Total = 89
Figure 2: Kidney biopsy histological diagnosis in patients with
NDKDormixedNDKD+DKD. NOS: not otherwise specified; GN:
glomerulonephritis.
Table 2: Kidney biopsy histological diagnosis of patients with
hematological conditions.
Histopathological diagnosis Number of cases
Membranous glomerulonephritis 3
Hypertensive renovascular disease 3
Light-chain deposition disease 3
Diabetic kidney disease 2
Chronic nephropathy—not otherwise specified 2
Membranoproliferative glomerulonephritis 2
Postinfectious glomerulonephritis 1




Table 3: Multivariate logistic regressionmodel for the prediction of
NDKD as a main diagnosis at kidney biopsy.
Variables OR (95% CI) pvalue
Age 1.017 (0.982–1.053) 0.356
Sex 0.667 (0.250–1.781) 0.419
Diabetes duration 0.969 (0.928–1.012) 0.153
Nephrotic syndrome 0.673 (0.282–1.604) 0.371
Diabetic retinopathy 0.183 (0.076–0.446 0.0001
Hematological condition 8.903 (1.047–75.725) 0.045
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can per se lead to kidney dysfunction and urinary abnor-
malities. Nevertheless, in our study, groups did not differ for
positive autoimmune (ANA, ANCA, and anti-PLA2R) or viral
serologies (HBV, HCV, and HIV). We acknowledge that the
relatively low number of patients under study could complicate
the identification of small differences between groups; how-
ever, similar results were obtained in a previous study involving
a larger cohort [11]. Even if, from the clinical standpoint, the
positivity of these elements could logically trigger a lower
“threshold” for kidney biopsy in diabetic patients, this behavior
is not presently corroborated by solid scientific data.
Conversely, our data suggest that the absence of DR in a
diabetic patient with kidney dysfunction and urinary ab-
normalities substantially strengthens the indication to
kidney biopsy. In our cohort of diabetic patients, the absence
of DR significantly predicted NDKD. Indeed, it has been
previously reported that DR has a high sensitivity for pre-
dicting DKD [18], and in a recent meta-analysis of 48
studies, this factor was one of the most consistently asso-
ciated with DKD among the studies considered [6].
We believe that themost relevant finding of our study is the
association between the presence of a hematological condition
and NDKD in kidney biopsy, which has not been clearly re-
ported before. (e occurrence of kidney diseases associated
with hematological conditions, especially monoclonal gam-
mopathies, in the absence of symptomatic MM or chronic
lymphocytic leukemia is increasingly recognized [19].(e term
monoclonal gammopathy of renal significance (MGRS) has
been created to identify these cases, and the classification of
MGRS is in continuous evolution, requiring the deployment of
different histopathological techniques (electron microscopy
analysis and immunofluorescence after pronase digestion),
often not widely available. Even if it is already accepted among
nephrologists that benign hematological conditions could
cause significant kidney pathology, our study provides further
evidence for considering MGUS (and similar disorders), in the
appropriate clinical setting, as possibly associated with kidney
diseases other than DKD in diabetic patients. Certainly, dia-
betic patients with coexisting hematological conditions and
kidney dysfunction and/or proteinuria could especially benefit
from kidney biopsy for diagnostic discrimination. We ac-
knowledge that a minority of our patients with hematological
condition and NDKD had a histological diagnosis that directly
demonstrated kidney involvement secondary to the condition
itself. Nonetheless, a number of diagnoses of mem-
branoproliferative glomerulonephritis, chronic neph-
ropathy—not otherwise specified—and membranous
glomerulonephritis were not further analyzed due to the lack of
electron microscopy examination and impossibility to perform
immunofluorescence after pronase digestion of tissue to
identify masked monotypical deposits [20]. Indeed, this could
have led to a possible diagnostic misclassification, inappro-
priately labeling a process as not secondary to the hemato-
logical condition. Whether the presence of MGUS could be
associated with renal diseases different from MRGS, possibly
representing an epiphenomenon of an autoimmune disorder is
presently not known.
We also highlighted a faster progression of CKD in patients
with DKD, compared with those with NDKD or mixed forms.
(is has been previously reported [7] and is likely related to the
fact that a significant proportion of patients with NDKD could
be proposed specific treatments, which can slow disease pro-
gression. On the contrary, it is also relevant to note that,
considering these data, a diagnosis of DKD in kidney biopsy
implies a worse kidney prognosis compared to NDKD. For this
reason, patients with DKD should be offered close monitoring
and intensive treatment to slower the progression of kidney
damage (i.e., strict glycemic control, judicious use of renin-
angiotensin-aldosterone blockers, aggressive blood pressure
control, and, whenever possible, new drugs that demonstrated to
improve renal prognosis, such as SGLT-2 inhibitors). We were































































































Figure 3: Kaplan–Meier curves for time to end-stage kidney disease (ESKD) (a) and time to death (b).
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group; indeed, our cohort was small and with a relatively short
follow-up.
Our study has several limitations. Importantly, an inherent
selection bias is evident since patients who were presumed to
have a high probability of DKD were excluded a priori, not
being offered kidney biopsy. Nevertheless, our data represent
an insight into the common practice of clinical nephrologists
and could apply to the population of diabetic patients who are
considered for kidney biopsy. We also acknowledge that our
study was monocentric, with a retrospective design and in-
cluding a relatively small number of patients, factors limiting
the generalizability of our findings.
5. Conclusions
In summary, our study confirms that, if carefully selected,
more than a half of kidney biopsies performed in diabetic
patients can identify NDKD (alone or with concomitant
DKD). (e strongest predictors of NDKD in kidney biopsy
in our cohort of diabetic patients were the absence of DR and
the coexistence of a hematological condition (especially
MGUS), and clinicians should maintain a low threshold for
kidney biopsy if these characteristics are met. Patients with
DKD progressed more rapidly to ESKD than patients with
NDKD or mixed forms; aggressive supportive therapy to
slower the progression of CKD should be warranted if DKD
is identified in kidney biopsy.
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